Amanta Healthcare Ltd
Q1 FY27, unaudited
- Revenue
- ₹68.80 Cr
- Profit after tax
- ₹3.31 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 68.80 | — | 287.68 |
| Other income | 0.64 | — | 3.37 |
| Total income | 69.45 | — | 291.05 |
| Employee benefit expense | 11.58 | — | 42.96 |
| Finance costs | 6.00 | — | 20.75 |
| Depreciation & amortisation | 4.69 | — | 18.73 |
| Total expenses | 64.95 | — | 267.29 |
| Profit before tax | 4.49 | — | 21.12 |
| Tax expense | 1.18 | — | 6.25 |
| Profit after tax | 3.31 | — | 14.88 |
| Total comprehensive income | 3.13 | — | 14.15 |
| Earnings per share, basic | ₹0.85 | ₹4.33 |
|---|---|---|
| Earnings per share, diluted | ₹0.85 | ₹4.33 |
Q1 FY27 — unaudited, from the company’s filing with NSE. Source
FY26 — unaudited, from the company’s filing with NSE. Source
Q1 FY27 results for every company Parakho holds
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Q1 FY27Amanta Healthcare reported Q1 FY27 revenue of INR69 crores, up roughly 5% year-on-year, with EBITDA of about INR15 crores and an EBITDA margin of approximately 22%. Management attributed cost pressure to a polymer price spike linked to the Middle East crisis and to overheads absorbed ahead of the delayed SteriPort Line 3 commissioning. The company detailed capex, timelines and expected margin impact from the SteriPort expansion, the SVP facility, and the newly commissioned captive solar power plant.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 65 published by the exchange
06 Oct 2026
05 Oct 2026
01 Oct 2026
01 Oct 2026
30 Sept 2026
30 Sept 2026
24 Sept 2026
Insider trading16 Sept 2026
FilingShareholder Meeting / Postal Ballot-Outcome of AGM
Appears 2 times in the recent filings shown; listed once.
16 Sept 2026
16 Sept 2026
Filing02 Sept 2026
25 Aug 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 06 Oct 2026.